NEW YORK (GenomeWeb) – German-Spanish DNA amplification and sequencing firm Sygnis today announced it has signed a patent transfer agreement providing certain rights to its Double Switch technology to Systasy Bioscience.

The Double Switch technology is for the qualitative and quantitative detection of protein-protein interactions, and as part of the deal, Systasy has purchased the patent covering the technology in a split version (Split TEV) for use with its EXTassay platform.

Sygnis retains the rights to Double Switch in its full-length version (Full TEV).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more

Jul
12
Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.